• 9231 Citations
  • 38 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Outputs

Filter
Meeting abstract
2019

Outcomes of the miltuximab first in human trial and proposed study design for a phase 1 trial 89zr/177lu theranostic trial

Campbell, D., Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Poursoultan, P., Ho Shon, K., Mackay, T., Roach, P., Bailey, D. & Walsh, B., 2019, In : European Urology, Supplements. 18, 1, p. e873 1 p., 655.

Research output: Contribution to journalMeeting abstract

Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.

Campbell, D., Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Poursoultan, P., Ho Shon, K., Mackay, T., Bailey, D. L., Roach, P. & Walsh, B., 2019, In : Journal of Clinical Oncology. 37, 7 Supplement, p. 261 1 p.

Research output: Contribution to journalMeeting abstract

2018

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Rini, B. I., Tannir, N. M., Escudier, B., McDermott, D. F., Grimm, M. O., Porta, C., Powles, T., Kollmannsberger, C. K., Gurney, H. P., Tykodi, S. S., Harrison, M., Heng, D. Y. C., Grünwald, V., Choueiri, T. K., Mekan, S., McHenry, M. B., Hammers, H. J., Motzer, R. J. & George, S., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii309-viii310 2 p.

Research output: Contribution to journalMeeting abstract

Open Access
File
1 Downloads (Pure)

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D., Choueiri, T. K., Necchi, A., Gerritsen, W. R., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Jensen, E., Frenkl, T., Perini, R. F. & Bajorin, D., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii320-viii321 2 p.

Research output: Contribution to journalMeeting abstract

Open Access
File

JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Motzer, R. J., Penkov, K., Haanen, J. B. A. G., Rini, B. I., Albiges, L., Campbell, M. T., Kollmannsberger, C. K., Negrier, S., Uemura, M., Lee, J. L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M. B., Wang, J., Robbins, P. B., Chudnovsky, A., Di Pietro, A. & Choueiri, T. K., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii724 1 p.

Research output: Contribution to journalMeeting abstract

Open Access
File

The biodistribution of Miltuximab® using Gallium-67 nuclear imaging: the MILGa-01 first in human trial

Sabanathan, D., Gurney, H., Trifunovic, M., Poursoultan, P., Shon, K. H., Sia, T. R., Wissmueller, S., Roach, P., Bailey, D. L., Campbell, D. & Walsh, B. J., 2018, In : BJU International. 122, S2, p. 32-33 2 p., 074.

Research output: Contribution to journalMeeting abstract

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

McDermott, D. F., Rini, B. I., Motzer, R. J., Tannir, N. M., Escudier, B., Kollmannsberger, C. K., Hammers, H. J., Porta, C., George, S., Donskov, F., Gurney, H. P., Grimm, M-O., Harrison, M., Hutson, T. E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A. & Powles, T., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii309 1 p.

Research output: Contribution to journalMeeting abstract

Open Access
File
2017

MILGa-01: a first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers

Gurney, H., Sabanathan, D., Gillatt, D., Poursoultan, P., Ho Shon, K., Walsh, B., Velonas, V., Thurecht, K. & Campbell, D., 2017, In : Journal of Clinical Oncology. 35, 6, 1 p., e565.

Research output: Contribution to journalMeeting abstract

Patient reported outcomes during long term treatment with PD-1 inhibitors focusing on chronic toxicity and quality of life

Man, J., Mercieca-Bebber, R., Habib, R., Carlino, M., Nagrial, A., Gao, B., Gurney, H., Wong, M. & Hui, R., 1 Nov 2017, In : Annals of Oncology. 28, Supplement 10, p. x192 1 p.

Research output: Contribution to journalMeeting abstract

Open Access
2 Citations (Scopus)
2016

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 66-66 1 p.

Research output: Contribution to journalMeeting abstract

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J. J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S3, p. 38 1 p., abs#113.

Research output: Contribution to journalMeeting abstract

Differences in the patterns of anti-pd1 (PD1) toxicity between tumor streams

Sabanathan, D., Kong, B., Byrne, N., Wegener, V., Eslick, G., Nagrial, A., Hui, R., Kefford, R., Gurney, H. & Carlino, M. S., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 68-68 1 p.

Research output: Contribution to journalMeeting abstract

MILGa-01-a first in human study assessing the safety and tolerability of chMIL-38 in prostate cancer

Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Magnussen, J., Poursoltan, P., Shon, K. H. O., Walsh, B. J., Mazure, H., Velonas, V., Thurecht, K., Quach Truong, Wissmueller, S. & Campbell, D., Aug 2016, In : BJU international. 118, Suppl. 1, p. 14-15 2 p.

Research output: Contribution to journalMeeting abstract

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Gurney, H., Guminski, A., Wong, S., Sabanathan, D. & Pavlakis, N., Jul 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, S3, p. 47 1 p., abs#209.

Research output: Contribution to journalMeeting abstract

2015

CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L. A., Waxman, I. M. & Motzer, R. J., Sep 2015, In : European Journal of Cancer. 51, Supplement 3, p. S708 1 p.

Research output: Contribution to journalMeeting abstract

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L-A., Waxman, I. M., Sharma, P. & 1 others, CheckMate 025 Investigators, Dec 2015, In : BJU international. 116, S5, p. 17 1 p.

Research output: Contribution to journalMeeting abstract

12 Citations (Scopus)
2013

Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation

Fox, P., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wilcken, N., Balleine, R. L. & Gurney, H., 20 May 2013, In : Journal of Clinical Oncology. 31, 15 supplement, p. 1-1 1 p., 543.

Research output: Contribution to journalMeeting abstract

19 Citations (Scopus)

Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation

Fox, P., Gao, B., Balakrishnar, B., Menzies, A. M., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wilcken, N., Balleine, R. L. & Gurney, H., 1 Jul 2013, In : Asia-Pacific Journal of Clinical Oncology. 9, Supplement 2, p. 45-45 1 p.

Research output: Contribution to journalMeeting abstract

2012

Accelerated BEP for metastatic germ cell tumors: combined analysis of Australian and UK phase I/II trials

Grimison, P. S., Chatfield, M. D., Mazhar, D., Toner, G. C., Chester, J. D., Stockler, M. R., Stark, D. P., Thomson, D. B., Shamash, J., Friedlander, M., White, J., Gebski, V., Wason, J., Boland, A. L., Rimmer, Y. L., McDonald, A., Gurney, H., Rosenthal, M., Singhal, N., Williams, M. V. & 2 others, Australian New Zealand Urogenital & West Anglia Cancer Research Network, 20 May 2012, In : Journal of Clinical Oncology. 30, 15 supplement, p. 4531-4531 1 p.

Research output: Contribution to journalMeeting abstract

Concomitant CYP2D6 inhibitor use and plasma metabolite levels in breast cancer patients treated with tamoxifen

Fox, P., Balakrishnar, B., Menzies, A., Liddle, C., Coulter, S., Provan, P., Gebski, V., Hui, R., Kefford, R., Wilcken, N., Balleine, R. & Gurney, H., 31 Jul 2012, In : Asia-Pacific Journal of Clinical Oncology. 8, Supplement 2, p. 52-52 1 p.

Research output: Contribution to journalMeeting abstract

CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen

Balakrishnar, B., Menzies, A. M., Ali, S. S., Yeap, S. H., Gao, B., Liddle, C., Coulter, S., Provan, P., Gebski, V., Hui, R., Kefford, R., Wilcken, N., Balleine, R. L. & Gurney, H., 20 May 2012, In : Journal of Clinical Oncology. 30, Supplement 15, p. 550-550 1 p.

Research output: Contribution to journalMeeting abstract

2011

Accelerated BEP for advanced germ cell tumors: an Australian multicenter phase I/II trial.

Grimison, P. S., Thomson, D. B., Stockler, M. R., Chatfield, M. D., Friedlander, M., Gebski, V., Boland, A. L., Houghton, B. B., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S. S., Lewis, C. R., Vasey, P. A., Toner, G. C. & Australian New Zealand Urogenital, 20 May 2011, In : Journal of Clinical Oncology. 29, 15 supplement, p. 4561-4561 1 p.

Research output: Contribution to journalMeeting abstract

49 Citations (Scopus)

The effect of pulmonary function testing on bleomycin dosing in germ cell tumors

Houghton, B. B., Grimison, P. S., Toner, G. C., Chatfield, M., Thomson, D. B., Friedlander, M., Gebski, V., Rosenthal, M., Gurney, H. & Stockler, M., 1 Mar 2011, In : Journal of Clinical Oncology. 29, 7 supplement, p. 227-227 1 p.

Research output: Contribution to journalMeeting abstract

2009

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: updated analysis of a randomized trial with 8 years follow-up

Grimison, P. S., Stockler, M. R., Thomson, D. B., Olver, I. N., Harvey, V. J., Gurney, H., Lewis, C. R., Gebski, V. J., Boland, A. L., Toner, G. C. & Australia New Zealand Germ Cell, 20 May 2009, In : Journal of Clinical Oncology. 27, 15, p. 5016-5016 2 p.

Research output: Contribution to journalMeeting abstract

1990

A phase-I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving intensive chemotherapy for small-cell lung-cancer

Anderson, H., Gurney, H., Radford, J., Steward, WP., Kamthan, A., Chang, J. & Thatcher, N., Sep 1990, In : British Journal of Cancer. 62, 3, p. 528-528 1 p.

Research output: Contribution to journalMeeting abstract

203 Citations (Scopus)

A phase-II study of ifosfamide and alpha-2 interferon (intron-A) in advanced non-small cell lung-cancer

Lind, MJ., Thatcher, N., Gurney, H. & Kamthan, A., Sep 1990, In : British Journal of Cancer. 62, 3, p. 502-502 1 p.

Research output: Contribution to journalMeeting abstract